CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Growing adoption of biosimulation software by regulatory bodies
4.1.2. Increase in R&D investments in the pharmaceutical and biotechnology industries
4.1.3. Need to curtail drug discovery and development costs
4.1.4. Growth in the biologics and biosimilars markets
4.2. Market Restraints & Challenges
4.2.1. Lack of standardisation
4.2.2. Shortage of biosimulation and modelling experts
4.3. Market Opportunities
4.3.1. Increased use of personalised medicine
4.3.2. Use of biosimulation solution for paediatric drug development
CHAPTER 5. GLOBAL BIOSIMULATION MARKET – BY APPLICATION
5.1. Drug Development
5.2. Drug Discovery
5.3. Other Applications
CHAPTER 6. GLOBAL BIOSIMULATION MARKET – BY PRODUCTS & SERVICES
6.1. Software
6.2. Services
CHAPTER 7. GLOBAL BIOSIMULATION MARKET – BY DELIVERY MODEL
7.1. Subscriptions Models
7.2. Ownership Models
CHAPTER 8. GLOBAL BIOSIMULATION MARKET – BY END USER
8.1. Pharmaceutical & Biotechnology Companies
8.2. Research Institutes
8.3. Contract Research Organizations
8.4. Regulatory Authorities
8.5. Others
CHAPTER 9. GLOBAL BIOSIMULATION MARKET - BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.2.4. Costa Rica
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Chile
9.3.4. Columbia
9.3.5. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Russia
9.4.7. Netherlands
9.4.8. Switzerland
9.4.9. Poland
9.4.10. Others
9.5. APAC
9.5.1. China
9.5.2. Japan
9.5.3. India
9.5.4. South Korea
9.5.5. Australia & New Zealand
9.5.6. Malaysia
9.5.7. Singapore
9.5.8. Others
9.6. Middle East & Africa
9.6.1. UAE
9.6.2. Saudi Arabia
9.6.3. Iran
9.6.4. Iraq
9.6.5. Qatar
9.6.6. South Africa
9.6.7. Algeria
9.6.8. Morocco
9.6.9. Nigeria
9.6.10. Egypt
9.6.11. Others
CHAPTER 10. GLOBAL BIOSIMULATION MARKET - COMPANY PROFILES
10.1 Certara Corporation
10.2 Simulation Plus
10.3 Dassault Systems
10.4 Schrödinger
10.5 Advanced Chemistry Development
10.6 Chemical Computing Group
10.7 Rosa
10.8 Genedata
10.9 Physiomics
10.10 Evidera
10.11 In Silico Biosciences
10.12 Leadinvent Technologies
10.13 Inosim Software
10.14 Nuventra Pharma
10.15. Insilico Biotechnology
CHAPTER 11. GLOBAL BIOSIMULATION MARKET - COMPETITIVE LANDSCAPE
11.1. Market Share Analysis
11.2. Strategies adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 12. MARKET INSIGHTS
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
CHAPTER 13. APPENDIX
13.1. List of Tables
13.2. List of Figures
